Back to top

Analyst Blog

ChemoCentryx, Inc. (CCXI - Snapshot Report) reported net loss of 28 cents per share in the first quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 27 cents but in line with the year-ago loss.

Revenues increased 89.3% to $1.9 million, slightly below the Zacks Consensus Estimate of $2 million. Revenues primarily consisted of collaborative research and development revenue from related party.

Operating expenses increased 29% during the quarter to $12.2 million. Research and development expenses increased 34% to $9.3 million. The increase was primarily attributable to the advancement of pipeline candidates. General and administrative expenses increased 15.7% to $3.0 million.

Pipeline Updates

The company’s pipeline includes vercirnon for Crohn’s disease and CCX140 for diabetic kidney disease. Vercirnon, the company’s most advanced candidate is being developed in collaboration with GlaxoSmithKline (GSK - Analyst Report). Top-line data from the SHIELD-1 phase III trial evaluating vercirnon for Crohn's disease is expected to be released in the second half of 2013. Additionally, interim results from a phase II study assessing CCX140 for diabetic nephropathy is expected in third quarter 2013.

We note that last month, ChemoCentryx completed its follow-on offer of 5.75 million shares at $12.00 per share. After adjusting for underwriter discounts, commissions and offering costs, the net proceeds to the company from the offering were approximately $64.4 million. The company plans to utilize the fund for accelerating CCX140 development and renal franchise expansion.

ChemoCentryx currently carries a Zacks Rank #3 (Hold). Stocks that look better and hold a Zacks Rank #2 include Onyx Pharmaceuticals, Inc. and WuXi PharmaTech (Cayman) Inc. (WX - Snapshot Report).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%